Screener
Charles River Laboratories CRL Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | June 27, 2026 | December 27, 2025 |
|---|---|---|
| Retained earnings | 1,372,295 | 1,388,620 |
| Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively | (323,189) | — |
| Accumulated other comprehensive loss | (195,989) | (171,783) |
| Total Charles River Laboratories International, Inc. equity | 2,839,636 | 3,164,630 |
| Nonredeemable noncontrolling interest | 6,354 | 5,301 |
| Total equity | 2,845,990 | 3,169,931 |
| Total liabilities, redeemable noncontrolling interests and equity | $7,532,145 | $7,135,422 |
| See Notes to Unaudited Condensed Consolidated Financial Statements. |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's noncontrolling interests in subsidiaries?
- Charles River Laboratories (CRL) reported noncontrolling interests in subsidiaries of $6.35M in Q2 2026.
- How has Charles River Laboratories's noncontrolling interests in subsidiaries changed year-over-year?
- Charles River Laboratories's noncontrolling interests in subsidiaries increased by 0.7% year-over-year, from $6.31M to $6.35M.
- What is the long-term trend for Charles River Laboratories's noncontrolling interests in subsidiaries?
- Over 5 years (2020 to 2025), Charles River Laboratories's noncontrolling interests in subsidiaries has grown at a 8.2% compound annual growth rate (CAGR), from $3.57M to $5.3M.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.
Ask your AI about Charles River Laboratories's noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude